The Metabolic Syndrome: Is It A Valid Concept? YES

Size: px
Start display at page:

Download "The Metabolic Syndrome: Is It A Valid Concept? YES"

Transcription

1 The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA

2 Global Projections for the Diabetes Epidemic: World 2011 = 366 M 2030 = 552 M >51% NAC 37.7 M 51.2 M 36% SACA 25.1 M 39.9 M 59% EUR 52.8 M WP 64.2 M MENA SEA 22% M AFR 14.7 M 28.0 M 90% 32.6 M 59.7 M 83% 71.4 M 121 M 69% M 60% M = million, AFR = Africa, NAC = North America and Caribbean, EUR = Europe, SACA = South and Central America, MENA = Middle East and North Africa, SEA = South-East Asia, WP = Western Pacific Diabetes Atlas Committee. Diabetes Atlas 5th Edition: IDF 2011.

3 Obesity Is the Primary Risk Factor for Type 2 Diabetes Age-adjusted relative risk of type 2 diabetes Men 1 Women < < BMI 1 Chan JM et al. Diabetes Care 1994;17: ; 2 Colditz G et al. Ann Intern Med 1995;122:

4 Age adjusted Percentage of U.S. Adults with Obesity or Diagnosed Diabetes Obesity (BMI 30 kg/m 2 ) O BE S I T Y Diabetes D IA No Data <14.0% % % % >26.0% B ET E S No Data <4.5% % % % >9.0% CDC s Division of Diabetes Translation. National Diabetes Surveillance System available at

5 The Dual Epidemic: Obesity and Diabetes 65% of adult Americans are overweight (BMI >25) and 32% are obese (BMI >30). 34% have the Metabolic Syndrome (ATP III criteria). There are now an estimated 25.8 million people with DM in the USA (11.3% of adults) and 79 million with prediabetes (IFG/IGT). The lifetime risk of developing DM for people born in 2000 is 33% for men and 39% for women. In this population CVD is the major cause of mortality.

6 Mortality in People With Diabetes: 50 Causes of Death 40 % of deaths Ischemic heart disease Other heart disease Diabetes Cancer Stroke Infection Other Geiss LS et al. In: Diabetes in America. 2nd ed. 1995; chap 11.

7 Diabetes and CVD Risk in Framingham Cohort Age Years: 30-Year Follow-up 10 P<0.001 P<0.001 Risk Ratio Men Women P<0.001 P<0.001 P<0.001 P<0.001 P< P<0.001 P< CHD Stroke Intermittent. Claudication Cardiac Failure CVD Total Wilson. Am J Kidney Dis. 1998;32(5 Suppl 3):S

8 Factors Implicated in Macrovascular Disease in Type 2 Diabetes Dyslipidemia Hypertension Nephropathy Obesity/sedentary lifestyle Altered coagulation, platelet function, and fibrinolysis Hyperinsulinemia/hyperproinsulinemia/insulin resistance Cigarette smoking Hyperglycemia Inflammation Modified from Bierman EL. Arterioscler Thromb. 1992;12:

9 MRFIT: Cholesterol and CVD Mortality in Men With Type 2 Diabetes Age-Adjusted CVD deaths per 10,000 person-years Controls Type 2 diabetes < Plasma cholesterol (mg/dl) Stamler et al. Diabetes Care. 1993;16:

10 Glycemia in Relation to Microvascular Disease and MI Incidence per 1,000 patient-years MI Microvascular disease UKPDS 35. BMJ 2000;321: Updated mean HbA 1C (%)

11 DECODE: Mortality Rate Increases With Increasing Hour Glucose (63/432) 15 (325/2766) 12 (146/909) 16 Mortality (%) 10 5 (1172/18,252) 6 0 Fasting glucose: <6.1 <7.0 (Not DM) <7.0 (Not DM) 7.0 (DM) 2-h glucose: < (IGT) 11.1 (DM) 11.1 (DM) (mmol/l) DECODE = Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe. Adapted from DECODE Study Group. Lancet. 1999;354:

12 What is a Syndrome? 1. A group of signs and symptoms that occur together and characterize a particular abnormality. 2. A set of concurrent things that usually form an identifiable pattern Ref. Merriam Webster s Collegiate Dictionary, 10 th Edition, 1997

13 13

14 The Insulin Resistance Syndrome Physical Inactivity Obesity (esp. Abdominal Obesity) Insulin Resistance Aging Atherogenic Dyslipidemia Elevated Blood Pressure Modified from S. Grundy MD Genetic Variation In CVD Risk Factor Regulation Hyperglycemia Proinflammatory State Prothrombotic State

15 How do we identify people clinically who have insulin resistance and increased CVD risk?

16 Metabolic Syndrome ATP III (3 of 5) Atherogenic Dyslipidemia Obesity (esp. Abdominal Obesity) TG 150 mg/dl HDL-C < 40 mg/dl (M) < 50 mg/dl (F) Elevated BP BP 130/85 mm Hg Waist Circumference Men: 102 cm (40 in) Women: 88 cm (35 in) Genetic Variation in CVD Risk Factor Regulation Insulin Resistance Proinflammatory State Prothrombotic State Fasting Glucose 100 mg/dl *(modified)

17 IDF Criteria: Obesity + 2 Others Atherogenic Dyslipidemia Obesity Waist (esp. Abdominal Circumference Obesity) Men: > 94 cm (37 in) Women: > 80 cm (31.5 in) TG> 150 mg/dl HDL-C < 40 mg/dl (M) < 50 mg/dl (F) Elevated BP BP > 130/85 mmhg (Population Specific) Genetic Variation In CVD Risk Factor Regulation Insulin Resistance Fasting Glucose >100 mg/dl Proinflammatory State Prothrombotic State

18 Metabolic Syndrome as a Precursor of CVD and DM2: The Framingham Offspring Study 1163 men and 1386 women, age 22-81, with no CVD or DM2 at baseline exam 4 & 8 yrs. Age-adjusted Prevalence of Metabolic Syndrome (modified ATP III criteria: FBG mg/dl) Men: Baseline 21.4% 8 Yr f/u 33.9% 56% increase Women: 12.5% 23.6% 47% increase Compared to those without Met Synd, those with Met Synd also had higher total and LDL Cholesterol and women had a higher rate of cigarette smoking Wilson, PWF et al. Circulation 2005;112:

19 Frequency of Risk Factors in Absence or Presence of Metabolic Syndrome Men Metabolic Syndrome Metabolic Syndrome Absent Present Waist >102 cm 14% 64% TG >150 mg/dl 15% 72% HDL-C <40 mg/dl 23% 78% BP >130/85 mmhg 43% 91% FBG mg/dl 11% 43% Women Waist >88 cm 11% 78% TG >150 mg/dl 6% 65% HDL-C <50 mg/dl 27% 85% BP >130/85 mmhg 34% 89% FBG mg/dl 5% 41% Wilson PWF et al. Circulation 2005; 112:

20 Men RR Age-Adjusted Signif. CVD 2.88 ( ) < Hard CHD 2.56 ( ) Total CHD 2.54 ( ) < DM ( ) < Women The Framingham Offspring Study Metabolic Syndrome and Age-Adjusted Risk for CVD and DM2 at 8 Years CVD 2.25 ( ) Hard CHD 2.50 ( ) Total CHD 1.54 ( ) DM ( ) < Wilson, PWF et al. Circulation. 2005;112:

21 Metabolic Syndrome Increases Risk for CHD and Type 2 Diabetes High LDL-C Metabolic Syndrome Type 2 Diabetes Coronary Heart Disease Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 2001;285:

22 Prevalence of Metabolic Syndrome in IGT & Diabetes IGT: 53% at baseline in the Diabetes Prevention Program Type 2 Diabetes: 65-85% in various studies

23 Multifactorial Intervention and Treatment Goals in Type 2 Diabetes: Steno-2

24 Multifactorial Intervention and CV Events in Type 2 Diabetes: Steno-2 50% RR

25 What can we learn from the Diabetes Prevention Program? About the prevalence and prevention of the Metabolic Syndrome in people with IGT? About the effect of the DPP interventions on the reduction of CVD risk?

26 Prevalence of Metabolic Syndrome at Randomization 1711 (53%) of the 3234 participants had the syndrome at randomization Prevalence of the syndrome did not vary by gender or age group (<45, 45 64, 65+ years) Prevalence did vary by ethnicity, being lowest in Asians (41%) and highest in Caucasians (57%) Prevalence of the individual components did vary by ethnicity and by age group

27 Cumulative Incidence of Metabolic Syndrome by Treatment Group Cumulative Incidence of Metabolic Syndrome (%) Risk reduction: 17%* by Metformin 41% # by Lifestyle Lifestyle vs Metformin 29% # Placebo Metformin Lifestyle 0.00 *p < 0.05; # p < Year from Randomization

28 Other Key Findings HTN was present in 30% of subjects at baseline; over 3 years it increased in the placebo and metformin groups, but significantly decreased in the ILS group TG decreased in all groups, but fell significantly more in ILS group ILS significantly increased HDL-C and decreased LDL Phenotype B After 3 yrs the use of medications to achieve targets for HTN was 27 28% less and for dyslipidemia was 25% less in the ILS group

29 3-Year Incidence (%) of Components by Treatment Group Placebo Metformin Lifestyle Waist Circ * 8* Low HDL-C High Trig * High FPG 40 29* 28* High BP * *p<0.001, comparison vs placebo

30 Effects of DPP Interventions on Reversal of the Metabolic Syndrome Placebo: reversal at 3.2 yrs 18% Metformin: " 23% Lifestyle: " 38% Overall prevalence of MS at 3.2 yrs Placebo: 61% +6% from baseline Metformin: 55% +2% " " Lifestyle: 42% -9% " "

31 Other Key Findings Mean baseline hscrp (5.9 mg/l) was increased in all groups and was higher in women than in men (median 4.9 vs 1.9 mg/l). Baseline hscrp correlated with BMI, waist circumference, FPG, and HOMA-IR. After 1 year the median change was: men: Placebo +5%, Met -7%, ILS -33% women: 0% -14% -29% The changes correlated mainly with weight loss and not with physical activity

32 Summary There is an epidemic of diabetes that is associated with lifestyle changes and obesity. The metabolic syndrome and IGT are more prevalent than diabetes. The metabolic syndrome and IGT are known risk factors for both type 2 diabetes and cardiovascular disease. Both lifestyle modification and medications are effective in preventing, delaying and treating type 2 DM and in reducing CVD risk factors.

33 My Conclusions YES-The Metabolic Syndrome is a useful clinical tool to identify people at high risk for type 2 diabetes and CVD The presence of one or more of the individual components of the Metabolic Syndrome should alert the clinician to check for and treat other related CVD risk factors A Global Approach to the treatment of diabetes must be the standard of care.

34 THANK YOU

Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?

Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes? Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes? Boston, MA November 7, 213 Edward S. Horton, MD Professor of Medicine Harvard Medical School Senior Investigator

More information

DIABETES. A growing problem

DIABETES. A growing problem DIABETES A growing problem Countries still grappling with infectious diseases such as tuberculosis, HIV/AIDS and malaria now face a double burden of disease Major social and economic change has brought

More information

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine

More information

Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk

Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic

More information

How to Reduce CVD Complications in Diabetes?

How to Reduce CVD Complications in Diabetes? How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year

More information

Epidemiology of Diabetes Mellitus in Asia

Epidemiology of Diabetes Mellitus in Asia Epidemiology of Diabetes Mellitus in Asia Nam H. Cho Professor of Preventive Medicine Director of Clinical Epidemiology Ajou University School of Medicine and Hospital, Suwon Korea President-elect of International

More information

Accelerated atherosclerosis begins years prior to the diagnosis of diabetes

Accelerated atherosclerosis begins years prior to the diagnosis of diabetes Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients

More information

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories

More information

Diabetes Day for Primary Care Clinicians Advances in Diabetes Care

Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:

More information

The Diabetes Link to Heart Disease

The Diabetes Link to Heart Disease The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM

More information

Welcome and Introduction

Welcome and Introduction Welcome and Introduction This presentation will: Define obesity, prediabetes, and diabetes Discuss the diagnoses and management of obesity, prediabetes, and diabetes Explain the early risk factors for

More information

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System

More information

Identification of subjects at high risk for cardiovascular disease

Identification of subjects at high risk for cardiovascular disease Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April 14 2011 Identification of subjects at high risk for cardiovascular disease Lars Rydén Karolinska Institutet

More information

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention

More information

Cardiovascular Disease After Spinal Cord Injury: Achieving Best Practice. Suzanne Groah, MD, MSPH Walter Reed Army Medical Center February 12, 2010

Cardiovascular Disease After Spinal Cord Injury: Achieving Best Practice. Suzanne Groah, MD, MSPH Walter Reed Army Medical Center February 12, 2010 Cardiovascular Disease After Spinal Cord Injury: Achieving Best Practice Suzanne Groah, MD, MSPH Walter Reed Army Medical Center February 12, 2010 CAVEAT LECTOR 2 CVD-related Mortality in Aging SCI GU

More information

Total risk management of Cardiovascular diseases Nobuhiro Yamada

Total risk management of Cardiovascular diseases Nobuhiro Yamada Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible

More information

Before the Pre. PREDIABETES Diagnosis, Management, Treatment. A few thoughts on diabetes.

Before the Pre. PREDIABETES Diagnosis, Management, Treatment. A few thoughts on diabetes. PREDIABETES Diagnosis, Management, Treatment Before the Pre A few thoughts on diabetes. James Lenhard, MD Director, Diabetes and Metabolic Diseases Center Christiana Care Health System JLenhard@ChristianaCare.org

More information

Metabolic Syndrome: Why Should We Look For It?

Metabolic Syndrome: Why Should We Look For It? 021-CardioCase 29/05/06 15:04 Page 21 Metabolic Syndrome: Why Should We Look For It? Dafna Rippel, MD, MHA and Andrew Ignaszewski, MD, FRCPC CardioCase presentation Andy s fatigue Andy, 47, comes to you

More information

Diabetes Mellitus: A Cardiovascular Disease

Diabetes Mellitus: A Cardiovascular Disease Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular

More information

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD

More information

The Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk

The Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk Update 2013 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine Denver Health

More information

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital 1. Importance of Lowering LDL-Cholesterol in Diabetes Patients & Lipid Guidelines Prevalence of dyslipidemia in Korea Prevalence

More information

Epidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk. Eberhard Standl

Epidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk. Eberhard Standl Epidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk Eberhard Standl European Heart House Sophia Antipolis Thursday, June 17, 2010 IDF Diabetes Atlas 2009: Global Numbers Still

More information

The Diabetes Prevention Program: Call for Action

The Diabetes Prevention Program: Call for Action The Diabetes Prevention Program: Call for Action Osama Hamdy, MD, PhD, FACE Medical Director, Obesity Clinical Program, Director of Inpatient Diabetes Management, Joslin Diabetes Center Harvard Medical

More information

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of

More information

The Clinical Unmet need in the patient with Diabetes and ACS

The Clinical Unmet need in the patient with Diabetes and ACS The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge

More information

Cardiovascular Complications of Diabetes

Cardiovascular Complications of Diabetes VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary

More information

Established Risk Factors for Coronary Heart Disease (CHD)

Established Risk Factors for Coronary Heart Disease (CHD) Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland

More information

American Academy of Insurance Medicine

American Academy of Insurance Medicine American Academy of Insurance Medicine October 2012 Dr. Alison Moy Liberty Mutual Dr. John Kirkpatrick Thrivent Financial for Lutherans 1 59 year old male, diagnosed with T2DM six months ago Nonsmoker

More information

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This

More information

Practical Diabetes. Nic Crook. (and don t use so many charts) Kuirau Specialists 1239 Ranolf Street Rotorua. Rotorua Hospital Private Bag 3023 Rotorua

Practical Diabetes. Nic Crook. (and don t use so many charts) Kuirau Specialists 1239 Ranolf Street Rotorua. Rotorua Hospital Private Bag 3023 Rotorua Practical Diabetes (and don t use so many charts) Nic Crook Rotorua Hospital Private Bag 3023 Rotorua Kuirau Specialists 1239 Ranolf Street Rotorua Worldwide rates of diabetes mellitus: predictions 80

More information

Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology

Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the

More information

Metabolic Syndrome in Asians

Metabolic Syndrome in Asians Metabolic Syndrome in Asians Alka Kanaya, MD Asst. Professor of Medicine, UCSF Asian CV Symposium, November 17, 2007 The Metabolic Syndrome Also known as: Syndrome X Insulin Resistance Syndrome The Deadly

More information

1. Which one of the following patients does not need to be screened for hyperlipidemia:

1. Which one of the following patients does not need to be screened for hyperlipidemia: Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:

More information

Objectives 10/11/2013. Diabetes- The Real Cost of Sugar. Diabetes 101: What is Diabetes. By Ruth Nekonchuk RD CDE LMNT

Objectives 10/11/2013. Diabetes- The Real Cost of Sugar. Diabetes 101: What is Diabetes. By Ruth Nekonchuk RD CDE LMNT Diabetes- The Real Cost of Sugar By Ruth Nekonchuk RD CDE LMNT Objectives To explain diabetes To explain the risks of diabetes To enumerate the cost of diabetes to our country To enumerate the cost of

More information

Why Do We Care About Prediabetes?

Why Do We Care About Prediabetes? Why Do We Care About Prediabetes? Complications of Diabetes Diabetic Retinopathy Leading cause of blindness in adults 1,2 Diabetic Nephropathy Leading cause of Kidney failure Stroke 2- to 4-fold increase

More information

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Know Your Number Aggregate Report Single Analysis Compared to National Averages Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics

More information

Review of guidelines for management of dyslipidemia in diabetic patients

Review of guidelines for management of dyslipidemia in diabetic patients 2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University

More information

Cedars Sinai Diabetes. Michael A. Weber

Cedars Sinai Diabetes. Michael A. Weber Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor

More information

CARDIOMETABOLIC SYNDROME

CARDIOMETABOLIC SYNDROME CARDIOMETABOLIC SYNDROME Prof. Gerald Yonga FESC, FACC Dept of Medicine, Aga Khan University East Africa Introduction Years after the term metabolic syndrome was first coined, controversy continues over

More information

Discussion points. The cardiometabolic connection. Cardiometabolic Risk Management in the Primary Care Setting

Discussion points. The cardiometabolic connection. Cardiometabolic Risk Management in the Primary Care Setting Session #5 Cardiometabolic Risk Management in the Primary Care Setting Sonja Reichert, MD MSc FCFP FACPM Betty Harvey, RNEC BScN MScN Amanda Mikalachki, RN BScN CDE S Discussion points Whom should we be

More information

Macrovascular Disease in Diabetes

Macrovascular Disease in Diabetes Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based

More information

5/28/2010. Pre Test Question

5/28/2010. Pre Test Question Myth of Metabolic Syndrome? C. W. Spellman, DO, PhD Professor and Associate Dean Research Dir. Center Diabetes and Metabolic Disorders Department Internal Medicine, Div. Endocrinology Texas Tech University

More information

Metabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah

Metabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Metabolic Syndrome Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Objectives Be able to outline the pathophysiology of the metabolic syndrome Be able to list diagnostic criteria for

More information

CVD Prevention, Who to Consider

CVD Prevention, Who to Consider Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..

More information

Diabetes Mellitus: Implications of New Clinical Trials and New Medications

Diabetes Mellitus: Implications of New Clinical Trials and New Medications Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October

More information

Type 2 Diabetes in Adolescents

Type 2 Diabetes in Adolescents Type 2 Diabetes in Adolescents Disclosures Paid consultant, Eli Lilly, Inc, Pediatric Type 2 Diabetes Clinical Trials Outline The burden of diabetes Treatment and Prevention Youth Diabetes Prevention Clinic

More information

Contents. I. CV disease and insulin resistance: Challenges and opportunities. II. Insulin sensitizers: Surrogate and clinical outcomes studies

Contents. I. CV disease and insulin resistance: Challenges and opportunities. II. Insulin sensitizers: Surrogate and clinical outcomes studies Contents I. CV disease and insulin resistance: Challenges and opportunities II. Insulin sensitizers: Surrogate and clinical outcomes studies IV. Identifying and treating patients with insulin resistance

More information

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Metabolic Syndrome Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Disclosure No conflict of interest No financial disclosure Does This Patient Have Metabolic Syndrome? 1. Yes 2. No Does This Patient

More information

Type 2 diabetes, the metabolic syndrome and cardiovascular disease in Europe

Type 2 diabetes, the metabolic syndrome and cardiovascular disease in Europe the metabolic syndrome and cardiovascular disease in Europe Diabetes Diabetes mellitus is a chronic disease which has been described as a state of raised blood glucose (hyperglycaemia) associated with

More information

Standards of Medical Care in Diabetes 2016

Standards of Medical Care in Diabetes 2016 Standards of Medical Care in Diabetes 2016 Care Delivery Systems 33-49% of patients still do not meet targets for A1C, blood pressure, or lipids. 14% meet targets for all A1C, BP, lipids, and nonsmoking

More information

The target blood pressure in patients with diabetes is <130 mm Hg

The target blood pressure in patients with diabetes is <130 mm Hg Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is

More information

Myths, Heart Disease and the Latino Population. Maria T. Vivaldi MD MGH Women s Heart Health Program. Hispanics constitute 16.3 % of US population!

Myths, Heart Disease and the Latino Population. Maria T. Vivaldi MD MGH Women s Heart Health Program. Hispanics constitute 16.3 % of US population! Myths, Heart Disease and the Latino Population Maria T. Vivaldi MD MGH Women s Heart Health Program Hispanics constitute 16.3 % of US population! 1 LEADING CAUSES OF DEATH IN LATINOS Heart disease is the

More information

Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine

Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine Setting the scene GB, 43 yo AA man followed for hypothyroidism returns on LT4 125 mcg/d and has a TSH=1.1

More information

ATP IV: Predicting Guideline Updates

ATP IV: Predicting Guideline Updates Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations

More information

Dyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram

Dyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III

More information

The Burden of the Diabetic Heart

The Burden of the Diabetic Heart The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than

More information

Kidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)

Kidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain) Kidney and heart: dangerous liaisons Luis M. RUILOPE (Madrid, Spain) Type 2 diabetes and renal disease: impact on cardiovascular outcomes The "heavyweights" of modifiable CVD risk factors Hypertension

More information

Fasting or non fasting?

Fasting or non fasting? Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues

More information

PREDIABETES TESTING SERVICES

PREDIABETES TESTING SERVICES PREDIABETES TESTING SERVICES ASSESSING DIABETES RISK IN ASYMPTOMATIC ADULTS Depending upon population characteristics, up to 70% of individuals with prediabetes will ultimately progress to diabetes at

More information

Rick Fox M.A Health and Wellness Specialist

Rick Fox M.A Health and Wellness Specialist Metabolic Diseases Rick Fox M.A Health and Wellness Specialist Metabolic Diseases Metabolism is the process your body uses to get or make energy from the food you eat. Food is made up of proteins, carbohydrates

More information

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy? Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists

More information

Pre-diabetes. Pharmacological Approaches to Delay Progression to Diabetes

Pre-diabetes. Pharmacological Approaches to Delay Progression to Diabetes Pre-diabetes Pharmacological Approaches to Delay Progression to Diabetes Overview Definition of Pre-diabetes Risk Factors for Pre-diabetes Clinical practice guidelines for diabetes Management, including

More information

Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre

Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Outline How big is the problem? Natural progression of type 2 diabetes What

More information

Cardiovascular Disease Prevention: Current Knowledge, Future Directions

Cardiovascular Disease Prevention: Current Knowledge, Future Directions Cardiovascular Disease Prevention: Current Knowledge, Future Directions Daniel Levy, MD Director, Framingham Heart Study Professor of Medicine, Boston University School of Medicine Editor-in-Chief, Journal

More information

Cardiovascular Management of a Patient with Diabetes

Cardiovascular Management of a Patient with Diabetes Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and

More information

MANAGING THE PRE-DIABETIC PATIENT

MANAGING THE PRE-DIABETIC PATIENT Managing the PreDiabetic Patient CAPA 2012 2 Key Questions MANAGING THE PRE-DIABETIC PATIENT Ingrid Lopes, DO 1. What is pre-diabetes and is it a disease? 2. What is the metabolic key? 3. When and how

More information

Prevenzione cardiovascolare e cambiamento degli stili di vita. Gian Franco Gensini

Prevenzione cardiovascolare e cambiamento degli stili di vita. Gian Franco Gensini Prevenzione cardiovascolare e cambiamento degli stili di vita Gian Franco Gensini Main causes of death worldwide at all ages (year:: 2005) 17.5 milion Preventing Chronic Diseases A vital investiment. WHO

More information

Eyes on Korean Data: Lipid Management in Korean DM Patients

Eyes on Korean Data: Lipid Management in Korean DM Patients Eyes on Korean Data: Lipid Management in Korean DM Patients ICDM Luncheon Symposium Sung Rae Kim MD PhD Division of Endocrinology and Metabolism The Catholic University of Korea Causes of Death in People

More information

Association between arterial stiffness and cardiovascular risk factors in a pediatric population

Association between arterial stiffness and cardiovascular risk factors in a pediatric population + Association between arterial stiffness and cardiovascular risk factors in a pediatric population Maria Perticone Department of Experimental and Clinical Medicine University Magna Graecia of Catanzaro

More information

Diabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center

Diabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center Diabetes and Heart Disease Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center No conflicts of interest or financial relationships to disclose. 2 What s the problem??

More information

The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease

The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease Steve Smith, Group Director Scientific Affairs, Diabetes & Metabolism GlaxoSmithKline R & D

More information

Preventive Cardiology Scientific evidence

Preventive Cardiology Scientific evidence Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention

More information

Cardiovascular Complications in Diabetes

Cardiovascular Complications in Diabetes What is all the fuss about? Cardiovascular Complications in Diabetes Dina Shrestha MD Consultant Endocrinologist Norvic International Hospital and Medical College Hospital for Advanced Medicine and Surgery

More information

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary

More information

Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome

Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome John E. Nestler, M.D. William Branch Porter Professor of Medicine Chair, Department of Internal Medicine Virginia Commonwealth University

More information

Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s

Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s Ho Chi Minh City, Vietnam August 7, 2014 JBS 2 Risk Guidelines (2005) Based

More information

Tuberculosis and Diabetes

Tuberculosis and Diabetes Tuberculosis and Diabetes National Web-based Seminar Francis J. Curry National TB Center San Francisco, California December 1, 29 Jane Kelly, M.D. Centers for Disease Control and Prevention jkelly@cdc.gov

More information

Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND CLASSIFICATION OF DIABETES

Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND CLASSIFICATION OF DIABETES Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND CLASSIFICATION OF DIABETES Objectives u At conclusion of the lecture the participant will be able to: 1. Differentiate between the classifications of diabetes

More information

Why is Earlier and More Aggressive Treatment of T2 Diabetes Better?

Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:

More information

Aggressive Lipid Management for Diabetes

Aggressive Lipid Management for Diabetes Aggressive Lipid Management for Diabetes Practical Ways to Achieve Targets in Diabetes Care Keystone, CO July 16, 2011 Robert H. Eckel, M.D. Professor of Medicine Professor of Physiology and Biophysics

More information

The National Diabetes Prevention Program in Washington State March 2012

The National Diabetes Prevention Program in Washington State March 2012 The National Diabetes Prevention Program in Washington State March 2012 Session Objectives 1. Overview of pre-diabetes. 2. Describe the Diabetes Prevention Program (DPP). 3. Eligibility for the DPP. 4.

More information

Diabetes, Diet and SMI: How can we make a difference?

Diabetes, Diet and SMI: How can we make a difference? Diabetes, Diet and SMI: How can we make a difference? Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Relative

More information

Diabetes. Health Care Disparities: Medical Evidence. A Constellation of Complications. Every 24 hours.

Diabetes. Health Care Disparities: Medical Evidence. A Constellation of Complications. Every 24 hours. Health Care Disparities: Medical Evidence Diabetes Effects 2.8 Million People in US 7% of the US Population Sixth Leading Cause of Death Kenneth J. Steier, DO, MBA, MPH, MHA, MGH Dean of Clinical Education

More information

The American Diabetes Association estimates

The American Diabetes Association estimates DYSLIPIDEMIA, PREDIABETES, AND TYPE 2 DIABETES: CLINICAL IMPLICATIONS OF THE VA-HIT SUBANALYSIS Frank M. Sacks, MD* ABSTRACT The most serious and common complication in adults with diabetes is cardiovascular

More information

Presenter Disclosure Information

Presenter Disclosure Information Prediabetes & Type 2 Diabetes Prevention Cari Ritter, PA-C Presenter Disclosure Information In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure

More information

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular

More information

Roadmap. Diabetes and the Metabolic Syndrome in the Asian Population. Asian. subgroups 8.9. in U.S. (% of total

Roadmap. Diabetes and the Metabolic Syndrome in the Asian Population. Asian. subgroups 8.9. in U.S. (% of total Diabetes and the Metabolic Syndrome in the Asian Population Alka Kanaya, MD Associate Professor of Medicine, UCSF Feb 26, 2010 Roadmap 1. Diabetes in Asian Americans Prevalence in the U.S. Risk factors

More information

well-targeted primary prevention of cardiovascular disease: an underused high-value intervention?

well-targeted primary prevention of cardiovascular disease: an underused high-value intervention? well-targeted primary prevention of cardiovascular disease: an underused high-value intervention? Rod Jackson University of Auckland, New Zealand October 2015 Lancet 1999; 353: 1547-57 Findings: Contribution

More information

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest

More information

Joslin Diabetes Center Primary Care Congress for Cardiometabolic Health 2013 The Metabolic Syndrome: Is It a Valid Concept?

Joslin Diabetes Center Primary Care Congress for Cardiometabolic Health 2013 The Metabolic Syndrome: Is It a Valid Concept? The Metabolic Syndrome: A Defeated Emperor What were (are) the problems? Well 1. There was no agreed upon pathogenic reason to identify people with the metabolic syndrome 2. It was a relatively poor way

More information

Addressing Addressing Challenges in Type 2 Challenges in Type 2 Diabetes Diabetes Speaker:

Addressing Addressing Challenges in Type 2 Challenges in Type 2 Diabetes Diabetes Speaker: Addressing Challenges in Type 2 Diabetes Geneva Briggs, PharmD,, BCPS Addressing Challenges in Type 2 Diabetes Speaker: Dr. Geneva Clark Briggs, a board-certified Pharmacotherapy Specialist, received her

More information

Preventing Diabetes K A R O L E. W A T S O N, M D, P H D, F A C C P R O F E S S O R O F M E D I C I N E / C A R D I O L O G Y

Preventing Diabetes K A R O L E. W A T S O N, M D, P H D, F A C C P R O F E S S O R O F M E D I C I N E / C A R D I O L O G Y Preventing Diabetes 2018 K A R O L E. W A T S O N, M D, P H D, F A C C P R O F E S S O R O F M E D I C I N E / C A R D I O L O G Y D A V I D G E F F E N S C H O O L O F M E D I C I N E A T U C L A CO-DIRECTOR,

More information

Donna Tomky, MSN, C-ANP, CDE, FAADE Albuquerque, New Mexico

Donna Tomky, MSN, C-ANP, CDE, FAADE Albuquerque, New Mexico Donna Tomky, MSN, C-ANP, CDE, FAADE Albuquerque, New Mexico Presented in Collaboration with New Mexico Health Care Takes On Diabetes Discuss the burden and challenges prediabetes presents in New Mexico.

More information

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease

More information

Complications of Pregnancy and Lifetime Risk to Health. Brian McCulloch MD Advocate Lutheran General Hospital September 26, 2015

Complications of Pregnancy and Lifetime Risk to Health. Brian McCulloch MD Advocate Lutheran General Hospital September 26, 2015 Complications of Pregnancy and Lifetime Risk to Health Brian McCulloch MD Advocate Lutheran General Hospital September 26, 2015 Pregnancy as a window to future health In 2005 the CDC stated that almost

More information

ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES

ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A

More information

Strategies for the prevention of type 2 diabetes and cardiovascular disease

Strategies for the prevention of type 2 diabetes and cardiovascular disease European Heart Journal Supplements (2005) 7 (Supplement D), D18 D22 doi:10.1093/eurheartj/sui025 Strategies for the prevention of type 2 diabetes and cardiovascular disease Jaakko Tuomilehto 1,2,3 *, Jaana

More information

On May 2001, the Third Adult

On May 2001, the Third Adult THE RISK OF DIABETES: CAN WE IMPACT CHD THROUGH THE ATP III CHOLESTEROL GUIDELINES? * Based on a presentation given by Steven M. Haffner, MD, MPH ABSTRACT Diabetes has been recognized among diabetologists

More information

How would you manage Ms. Gold

How would you manage Ms. Gold How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56

More information